inappropriate use, it is important to determine which users become inappropriate users. To date, the determinants of inappropriate use have not been investigated. Only the determinants of long-term use have been studied, yet with inconsistent results and without considering the other aspects of inappropriate use (i.e., dosage and number of BZD types used). In those studies, sex, [29] [30] [31] age, [28] [29] [30] [31] [32] [33] education, 32 psychopathology, [32] [33] [34] physical health, 30, 33, 34 pain complaints, 34 daily BZD use, 28 use of higher potency BZDs, 31 and antidepressants 33 were identified as correlates of long-term BZD use.
To the best of our knowledge, we are the first study to investigate the relative importance of a comprehensive set of potential correlates of BZD use and inappropriate use in a study among 2852 subjects at various stages of psychopathology participating in the Netherlands
Study of Depression and Anxiety (NESDA). We first explored the sociodemographic, psychological and physical correlates of BZD use.
Second, we investigated (the correlates of) inappropriate use according to international guidelines. [25] [26] [27] MAteriALs AND MetHoDs subjects Subjects participated in the baseline assessment of the Netherlands Study of Depression and Anxiety (NESDA), an 8-year longitudinal cohort study of 2981 respondents aged 18 to 65 years. 35 NESDA was designed to be representative of individuals with depressive and/or anxiety disorders in different health care settings and developmental stages of illness. 35 Psychiatric status did not seem to be predictive of the initial (non)-response in the NESDA study. (Non)-response was driven by age and sex,
i.e. older women more often participated in the NESDA study and young men less often. 35 Subjects were recruited from the community, general practice and specialized mental health care institutions throughout the Netherlands. They completed a medical exam, an in-person interview,
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and several self-report questionnaires. The study protocol was approved by the Ethical Review Board of each participating centre and all subjects signed an informed consent at the baseline assessment.
We excluded subjects with one or more missing values on BZD use, inappropriate use, sociodemographic, psychological or physical characteristics (n=94). An exception was made for missing values on the Insomnia Rating Scale (IRS) where mean imputation was used due to the high number of missings (n=300). We also excluded subjects with epilepsy (n=29), as epilepsy is an indication that justifies prolonged BZD use. 36 To obtain an indication of the main correlates of BZD use (aim BZDs were classified as ATC-coded groups N05BA, N05CD, N05CG, and N03AE01. The so called "Z-drugs", of which in the Netherlands only zopiclone and zolpidem (ATC code N05CF) are available, were also included in our analyses, as studies on long-term adverse effects, withdrawal and tolerance development for these drugs are still lacking.
The daily BZD dose was computed according to the coding system of the ATC and DDD system. 37 The Mean Daily Dose was calculated by dividing individual daily doses (in mg) of BZDs by the DDD for the particular BZD. 38 For patients using BZDs other than diazepam, an equivalent daily dose was calculated with the conversion tables commonly used by general practitioners' (GPs) 39 were assessed with the Beck Anxiety Inventory (BAI). 41 The presence of insomnia was determined using the Insomnia Rating Scale (IRS). 42 The severity of depressive symptoms was measured by the cognitive/mood scale of the Inventory of Depressive Symptomatology Self Report (IDS-SR). 43 In order to avoid overlap with the BAI and IRS, we did not include 
resULts characteristics of BZD Use
Of the 2852 subjects, 429 (15.0%) had used a BZD in the past month. 
Appropriateness of BZD Use
In 1 Expressed as diazepam equivalents, 2 DDD indicates defined daily dose (DDD for diazepam: 10 mg / day), 3 an appropriateness score of 0 indicates that all appropriateness criteria are met (appropriate use), an appropriateness score of 3 indicates that none of the criteria is met (inappropriate use) Median (interquartile range) is given for mean daily dose and duration of use. Percentages are given for categorical variables. 1 Inappropriate BZD use is calculated with an inappropriateness score. An inappropriateness score of 0 indicates that all appropriateness criteria are met, an inappropriateness score of 3 indicates that none of the criteria is met. All variables with P < 0.10 are entered in the multivariate model. Significance in the multivariate analysis is inferred at P < 0.05. met all three appropriateness criteria, whereas 64.3% met two criteria, 13.8% met one and 6.8% of users did not meet any criterion (highly inappropriate use). Table 4 Although the uncritical enthusiasm about BZD use is over since many decades, 30, 47, 48 BZDs are still not only used for the treatment of severe insomnia and anxiety (other than epilepsy), but also to alleviate stress caused by adverse life circumstances such as unemployment 49 as well as pain 6 and other somatic complaints. As could be expected, anxiolytic BZDs were more often used in cases of anxiety disorders, and hypnotic BZDs more often in cases of insomnia. However, it also seems that the drugs are insufficient to provide therapeutic relief as otherwise lower anxiety and insomnia scores were to be expected in the respective groups. Group differences on age and agreeableness were unexpected and difficult to explain.
In general, the high percentage of inappropriate users in NESDA is disconcerting. The majority (84.8%) of users did not use BZDs according to international guidelines, [25] [26] [27] mainly due to exceeding the maximum duration of recommended use. This is striking considering that for more than 20 years BZDs have been known to cause side effects and dependence and evidence for the drug's effectiveness in long-term use is controversial. 7, 8 In addition, several NESDA subjects surpassed the recommended daily dosage (14.0%) and used more than one type of BZD concomitantly (15.6%). Dosage escalation is generally unsafe, as side effects become more pronounced and can have adverse consequences ranging from low performance at work to falls and traffic accidents. 6, [20] [21] [22] BZDs should be reserved for the severely anxious who have tried AD medication with no effect and have BZDs as last treatment option.
However, BZD prescriptions cannot be discontinued without providing patients with alternative coping strategies. Training should be conducted to strengthen BZD users' coping skills, 11, 58 self-efficacy and positive outcome expectations 11 and to lessen their disengagement beliefs 11 as such efforts may increase the chance of successful BZD discontinuation. 11, 58 In spite of all objections and in view of the restricted financial resources in the health sector, it is clear that prescribing BZDs takes less time than providing psychological support. 7, 55 Therefore, BZD use should be targeted with relatively quick and cheap methods that have been developed (e.g., computer-tailored education, 11 discontinuation letters 59 ) and found to increase effectively BZD cessation rates.
11,59
The present study has some limitations. The cross-sectional design does not allow us to make causal inferences on whether determinants preceded BZD use or vice versa. Although participants were asked to bring drug containers to the interview, one fourth of the subjects did not adhere to that and reported medication use from memory leading to a potential recall bias. The 84.8% inappropriate user number is probably an overestimation, as long-term users were more likely to be included in the user group than short-term users due to the cross-sectional design. A strong aspect of our study is the conductance of a multivariate analysis across a comprehensive set of possible determinants of BZD use. Furthermore, we included all aspects of inappropriate BZD use in a large sample composed of subjects with a range of psychopathology.
In conclusion, this study revealed three major points: 1) the vast majority of NESDA subjects displayed inappropriate BZD use, mainly due to exceeding the maximum duration of recommended use; 2) it is primarily the physically or mentally vulnerable subjects who use BZDs, and 3) the most physically ill of the BZD users are at highest risk for inappropriate use. Without further evidence for the effectiveness of BZDs in long-term use, caution in initiating BZD prescriptions is recommended, particularly when patients are chronically ill and old, as these subjects are most likely to display inappropriate use.
